Title: Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve
 individuals with Long COVID

3

Authors: Connor B Grady<sup>1,2,\*</sup>, Bornali Bhattacharjee<sup>3,4,\*</sup>, Julio Silva<sup>3,\*</sup>, Jillian Jaycox<sup>3</sup>, Lik Wee
Lee<sup>6</sup>, Valter Silva Monteiro<sup>3</sup>, Mitsuaki Sawano<sup>7</sup>, Daisy Massey<sup>7</sup>, César Caraballo<sup>7,8</sup>, Jeff R.
Gehlhausen<sup>3</sup>, Alexandra Tabachnikova<sup>3</sup>, Tianyang Mao<sup>3</sup>, Carolina Lucas<sup>3</sup>, Mario A. PeñaHernandez<sup>3,4</sup>, Lan Xu<sup>3</sup>, Tiffany J. Tzeng<sup>3</sup>, Takehiro Takahashi<sup>3</sup>, Jeph Herrin<sup>8</sup>, Diana Berrent
Güthe<sup>9</sup>, Athena Akrami<sup>10,11</sup>, Gina Assaf<sup>11</sup>, Hannah Davis<sup>11</sup>, Karen Harris<sup>9</sup>, Lisa McCorkell<sup>11</sup>,
Wade L Schulz<sup>5,7,12</sup>, Daniel Grffin<sup>13</sup>, Hannah Wei<sup>11</sup>, Aaron M Ring<sup>3</sup>, Leying Guan<sup>5,14</sup>, Charles
Dela Cruz<sup>4,5,15</sup>, Akiko Iwasaki<sup>3,5,16,†</sup>, Harlan M Krumholz<sup>5,7,17,18,†</sup>

11

### 12 Affiliations:

- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine,
   University of Pennsylvania, Philadelphia, Pennsylvania.
- 15 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,16 Massachusetts.
- 17 3. Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.
- 18 4. Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven,
- 19 Connecticut, USA.
- 20 5. Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut.
- 21 6. Adaptive Biotechnologies, Seattle, WA, USA.
- 22 7. Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven,
- 23 Connecticut.
- 24 8. Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
- 25 9. Survivor Corps.
- 26 10. Sainsbury Wellcome Centre, University College London, London, UK.
- 27 11. Patient-Led Research Collaborative.
- 28 12. Department of Laboratory Medicine, Yale University School of Medicine, New Haven,
- 29 Connecticut.
- 30 13. Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons,
- 31 New York City, New York.

- 32 14. Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut
- 33 15. Department of Medicine, Section of Pulmonary and Critical Care Medicine, Yale University
- 34 School of Medicine, New Haven, Connecticut.
- 35 16. Howard Hughes Medical Institute, Chevy Chase, Maryland.
- 36 17. Department of Health Policy and Management, Yale School of Public Health, New Haven,
- 37 Connecticut.
- 38 18. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of
- 39 Medicine, New Haven, Connecticut.
- 40
- 41
- 42 \*: Indicates equal contribution
- 43 †: Co-senior and corresponding authors
- 44 Correspondence can be addressed to: <u>akiko.iwasaki@yale.edu</u> and <u>harlan.krumholz@yale.edu</u>
- 45
- 46
- .0
- 47
- 48
- 49
- 50
- 50
- 51
- 52
- 54
- 53
- 54
- 55
- 56
- 57
- 58

#### 59 Abstract

Background: Long COVID contributes to the global burden of disease. Proposed root cause
hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation
of latent herpesviruses. Patients have reported various changes in Long COVID symptoms after
COVID-19 vaccinations, leaving uncertainty about whether vaccine-induced immune responses
may alleviate or worsen disease pathology.

#### 65 Methods

66 In this prospective study, we evaluated changes in symptoms and immune responses after COVID-

67 19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered

68 before vaccination and then at 2, 6, and 12 weeks after receiving the first vaccine dose of the

69 primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific

70 antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines

71 were quantified before vaccination and at 6 and 12 weeks after vaccination.

#### 72 **Results**

73 Self-report at 12 weeks post-vaccination indicated 10 out of 16 participants had improved health,

- 74 3 had no change, 1 had worse health, and 2 reported marginal changes. Significant elevation in
- 75 SARS-CoV-2-specific TCRs and Spike protein-specific IgG were observed 6 and 12 weeks after

76 vaccination. No changes in reactivities were observed against herpes viruses and self-antigens.

77 Within this dataset, higher baseline sIL-6R was associated with symptom improvement, and the

78 two top features associated with non-improvement were high IFN-β and CNTF, among soluble

analytes.

### 80 Conclusions

Our study showed that in this small sample, vaccination improved the health or resulted in no change to the health of most participants, though few experienced worsening. Vaccination was associated with increased SARS-CoV-2 Spike protein-specific IgG and T cell expansion in most individuals with Long COVID. Symptom improvement was observed in those with baseline elevated sIL-6R, while elevated interferon and neuropeptide levels were associated with a lack of improvement.

- 87
- 88
- 89

#### 90 Plain language summary

91 The impact of the COVID-19 vaccine on vaccine-naïve individuals suffering from Long COVID 92 is uncertain. This study assessed the experience and immune signatures of 16 unvaccinated 93 participants with Long COVID. A total of 10 participants had improved health status after 94 vaccination, and one person reported only worsening health. As expected, vaccination increased 95 immune cells and antibodies against the viral spike protein. Immune signatures may prove to be 96 predictors of health status after vaccination. However, given the small number of participants, 97 these initial findings need further validation.

98

99

### 100 Introduction

Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), is a debilitating condition following acute SARS-CoV-2 infection.<sup>1-6</sup> It can significantly impact people's lives, including their ability to return to work and engage in other social activities.<sup>7,8</sup> Although investigators have launched several prospective clinical trials of Long COVID treatment,<sup>9–12</sup> no definitive therapies exist.

Viral persistence is a possible contributing factor for Long COVID.<sup>13–15</sup> So far, several reports have suggested the persistence of active SARS-CoV-2 reservoirs in Long COVID patients<sup>16,17</sup> and that vaccination could assist in clearing persistent virus. However, the impact of vaccination after developing Long COVID remains unclear.<sup>18</sup> In a recent study, Nayyerabadi et al. reported the alleviation of symptoms, an increase in WHO-5 well-being scores, and a decrease in inflammatory cytokines after vaccination among participants with Long COVID.<sup>19</sup>

At the same time, there are concerns that the vaccine's spike protein or innate immune stimuli induced by the lipid nanoparticles and mRNA may exacerbate Long COVID symptoms by activating immunological pathways.<sup>14,20</sup> These concerns have contributed to vaccine hesitancy among individuals with Long COVID.<sup>21</sup> Consequently, it is crucial to investigate the effect of vaccination on Long COVID symptoms.

Accordingly, we launched the Yale COVID-19 Recovery Vaccine Study: Measuring Changes in Long Covid Symptoms After Vaccination (NCT04895189), a prospective, unblinded, observational study to evaluate changes in Long COVID symptoms, their prevalence, and burden. Immune responses before and after receiving the COVID-19 vaccine were evaluated to assess vaccine responses and identify factors associated with health outcomes in vaccine-naïve individuals with Long COVID.<sup>22</sup> This report presents findings from 16 participants recruited between May 3, 2021, and February 2, 2022.

124

#### 125 Methods

#### 126 Study design

A pre-post, prospective observational study was conducted among unvaccinated individuals experiencing Long COVID symptoms who intended to receive a COVID-19 vaccine as part of the routine clinical care (ClinicalTrials.gov Identifier: NCT04895189). Participants completed a survey before vaccination to collect demographic and acute COVID-19 infection information and

131 their baseline (i.e., pre-vaccination) Long COVID symptom experience (survey included in the 132 Supplementary file). Participants were vaccinated with any approved COVID-19 vaccine and 133 then asked to complete three follow-up surveys at 2, 6, and 12 weeks after receiving the first 134 vaccine dose of the primary series. SARS-CoV-2 specific humoral responses, responses to 135 common viral pathogens and autoantigens, T-cell repertoire sequencing, and soluble immune 136 modulators were quantified in a subset of participants before vaccination and at 6 ( $\bar{x}$ : 6.6) and 12 137  $(\bar{x}: 13.4)$  weeks after vaccination. This study was approved by the Yale University Institutional 138 Review Board (IRB #2000030423).

139

#### 140 **Patient involvement**

141 Patient advocacy groups were actively engaged in the conception and design of the study. The idea for the study originated from a Survivor Corps poll posted to their Facebook page, many 142 143 of whom had COVID-19 and suffered from Long COVID. Their poll showed that 40% of 144 respondents with self-reported Long COVID had mild to full symptom resolution after vaccination 145 while 14% reported worsening of their symptoms. In response, hypotheses were developed as to how vaccination might impact Long COVID symptoms.<sup>23,24</sup> Survivor Corps aided in participant 146 147 recruitment. The Patient-Led Research Collaborative, a self-organized group of Long COVID 148 patient-researchers working on patient-led research around the Long COVID experience, was 149 enlisted to contribute to the study design. Both groups advocated for including individuals without 150 a positive PCR test for SARS-CoV-2 and helped develop study surveys. Surveys were also informed by prior survey studies.<sup>7,25–29</sup> 151

152

#### 153 Eligibility

Eligible individuals included unvaccinated individuals 12 years or older who self-reported Long COVID (based on the presence of symptoms that started after COVID-19 and persisted more than two months) and planned to receive the COVID-19 vaccine. To verify past COVID-19 illness, individuals must have had a positive COVID-19 test (PCR or antigen) more than two months prior, have had a positive COVID-19 antibody or T-cell test, have been hospitalized for COVID-19, or have been diagnosed by a clinician as having COVID-19. Participants also had to be willing to travel to New Haven, Connecticut to provide blood and saliva samples. Recruitment was

161 conducted through social media advertisements and patient support groups. Participants were not162 compensated for their involvement.

163

#### 164 **Outcomes**

165 The primary outcome was whether individuals' overall health condition improved, stayed 166 the same, or worsened after receiving a COVID-19 vaccine. Secondary outcomes included changes 167 in symptom prevalence and severity and associated changes in immune response to the COVID-168 19 vaccine. The immunophenotyping assays included the detection of SARS-CoV-2-specific 169 antibody responses, SARS-CoV-2 specific T cell enrichment, antibody responses to other common 170 viruses and quantitation of soluble immune mediators.

171

#### 172 **Data collection**

173 Before vaccination, demographic, acute COVID-19, and persistent symptom information was 174 collected by survey. Participants were asked to rate their symptoms in terms of how much physical 175 pain or discomfort the symptom caused ("physical effects") and how much each symptom 176 impaired their social or family functioning compared to before infection ("social effects") on a 5-177 level Likert scale from "not at all" to "very much" (Supplementary table 1). We provided a list 178 of 125 symptoms developed through a literature review and prior Long COVID symptoms 179 lists.<sup>7,8,26</sup> Participants were asked the same questions on the three post-vaccination surveys (2, 6, 180 and 12 weeks after vaccination). Overall health change was measured with the question, "Would 181 you say that your overall health, as compared to your health before the vaccine, is worse, better, 182 or the same?" at 2, 6, and 12 weeks after vaccination. Data collection was performed using RedCap 183 version 12.0.25 (Vanderbilt University). All survey data were self-reported. Blood samples were 184 collected on-site before vaccination and at 6 and 12 weeks after vaccination. Further information 185 on the study's design, eligibility criteria, and data collection are available online.<sup>22</sup>

186

#### 187 **Biospecimen processing**

Whole blood was collected in sodium-heparin-coated vacutainers (BD 367874, BD Biosciences) and EDTA-coated vacutainers (BD 367856, BD Biosciences). For each participant, unique study identifiers were provided upon collection. Plasma samples were collected after centrifugation of whole blood at 600×g for 10 minutes at room temperature (RT) without brake

from sodium-heparin-coated tubes as previously described.<sup>30</sup> The blood samples collected in
 EDTA-coated tubes were frozen and subsequently shipped to Adaptive Biotechnologies for TCR
 sequencing.

195

#### 196 Quantitation of SARS-CoV-2 specific antibody levels by ELISA

ELISA assays were performed as previously described.<sup>30</sup> Briefly, MaxiSorp plates (96 197 198 wells; 442404, Thermo Scientific) were coated with recombinant SARS-CoV-2 S1 (S1N-C52H3-199 ACROBiosystems), receptor-binding domain (RBD) (SPD-C52H3-100 µg. 100 µg, 200 ACROBiosystems) and the nucleocapsid protein (NUN-C5227-100 µg, ACROBiosystems) at a 201 concentration of 2 µg/ml in PBS and were incubated overnight at 4 °C. The primary antibodies 202 used for the standard curves were human anti-spike (SARS-CoV-2 human anti-spike [AM006415; 203 91351, Active Motif]) and human anti-nucleocapsid (SARS-CoV-2 anti-nucleocapsid [1A6; MA5-204 35941, Active Motif]) and HRP anti-human IgG antibody (1:5,000; A00166, GenScript) was the 205 secondary antibody.

206

#### 207 TCR sequencing & SARS-CoV-2 Specific TCR assignment

208 Immunosequencing of the third complementarity determining (CDR3) regions of TCR- $\beta$ 209 chains was carried out using ImmunoSEQ Assays (Adaptive Biotechnologies). Samples were 210 classified as positive or negative for detection and enrichment of COVID-specific T cells using 211 four of Adaptive's COVID-19 classifiers: V1 classifier, V3 classifier, spike classifier and non-212 spike classifier. The V1 classifier was trained comparing peripheral repertoires from acute COVID and convalescent subjects with control samples collected pre-pandemic.<sup>31,32</sup> The V3 classifier was 213 214 trained on a larger dataset that included subjects with natural infection as well as those that were 215 vaccinated as positive cases. The sequences in the V3 classifier were cross-referenced against data 216 from MIRA (multiplexed antigen-stimulation experiments) experiment to develop two additional classifier.<sup>32,33</sup> The spike classifier identifies the spike-specific signal while the non-spike classifier 217 218 (with vaccinated samples included as controls) identifies natural infection using the non-spike 219 signal. T cell responses are categorized as negative, positive, and "No Call" (representing samples 220 with an insufficient number of T cell rearrangements to make a definitive negative call).

221

#### 222 Rapid Extracellular Antigen Profiling (REAP) Library Expansion

223 The new yeast library (Exo205) containing 6,452 unique antigens was used. IgG isolations 224 and REAP selections were done as previously described.<sup>30</sup> Briefly, participant IgGs were purified 225 from plasma using protein G magnetic beads and yeast-reactive IgGs were initially removed by 226 adsorption to yeast transformed with the pDD003 empty vector. A total of 10<sup>8</sup> induced Exo205 227 yeast cells were washed with PBE and incubated with 10 µg of purified participant IgGs in 228 duplicate. IgG bound yeast cells were selected by anti-human IgG Fc antibody binding (clone 229 QA19A42, Biolegend) and next generation sequencing (NGS) was carried out to identify epitopes 230 based on the protein display barcode on yeast plasmids. REAP scores were calculated as described 231 previously.30

232

### 233 Multiplex proteomic analysis

234 Frozen patient plasma was shipped to Eve Technologies (Calgary, Alberta, Canada) on dry 235 ice to run 13 multiplex panels: Human Cytokine/Chemokine 71-plex Discovery Assay (HD71), 236 Human Cytokine P3 Assay (HCYP3-07), Human Cytokine Panel 4 Assay (HCYP4-19), Human 237 Complement Panel Assay (HDCMP1), Human Myokine Assay (HMYOMAG-10), Human 238 Neuropeptide Assay (HNPMAG-05), Human Pituitary Assay (HPTP1), Human Adipokine Panel 239 2 Assay (HADK2-03), Human Cardiovascular Disease Panel Assay (HDCVD9), Human CVD2 240 Assay (HCVD2-8), Steroid/Thyroid 6plex Discovery Assay (STTHD) Human Adipokine Assay 241 (HDADK5), and TGF-Beta 3-plex Discovery Assay (TGFβ1-3). Samples were sent in two batches 242 with internal controls in each shipment to assess effectiveness of batch correction as described 243 below.

To harmonize data across the two batches, ComBat was used, an empirical Bayes method available through the "sva"<sup>34</sup> R package (version 3.4.6), designating the initial batch as the reference and incorporating the following covariates: disease status, sex, age, and hormone conditions. The effectiveness of the ComBat was validated using sample replicates between each batch in a matched pairs analysis. Analytes that exhibited significant differences post-correction were excluded from further analysis.

250

#### 251 Statistical analysis

We prospectively sought to enroll 50-100 participants to evaluate overall health and symptom changes. However, the study was terminated early due to an inability to reach the target

sample size given that few people with Long COVID were vaccine naïve. Our final cohort comprised participants who met eligibility, completed the baseline survey, and were vaccinated at least once.

Cohort characteristics were reported as frequencies with proportions or medians with ranges. The overall health condition of participants after vaccination compared to before vaccination was described as the proportion of individuals with each response (i.e., better, worse, the same, don't know) at each post-vaccination time point out of the number of individuals with a submitted survey at that time point.

For other symptom-related analyses, participants' Likert scale responses to the physical and social effects associated with each symptom were coded numerically (**Supplementary table** 1). The proportion of symptoms experienced was calculated at each survey as the number of participants experiencing each symptom (i.e., symptom reported and non-zero response to the physical or social effect scales) out of the participants who completed the given survey.

267 The burden of each participant's symptoms was summarized by summing across their 268 responses to the symptom physical and social effect scales, separately, for each survey. Scores 269 could range from 0 to 500 per survey (i.e., 125 symptoms per survey with a maximum score of 4). 270 Higher values suggest greater symptom burden, and a value of 0 suggests no symptom burden. 271 Changes in these values indicates a change in the number of symptoms experienced, the symptom severity, or both. We report the median, 2<sup>nd</sup> and 3<sup>rd</sup> quartiles, and range for each survey and effect 272 273 (i.e., physical and social). Differences between surveys were not tested. Analyses were performed 274 in R (v 4.2.2; R Foundation for Statistical Computing, Vienna, Austria).<sup>35</sup>

275 Differences in SARS-CoV-2 specific T-cell responses, anti-SARS-CoV-2 antibody 276 responses measured by ELISA and REAP before and after vaccination were assessed using 277 Wilcoxon matched-pairs signed rank tests. To assess correlation between observed T-cell 278 responses and antibody levels as well as to determine concordance between the two different 279 methods of determining anti-SARS-CoV-2 antibody levels, Spearman rank correlations were 280 calculated. The correlation coefficients between assays were used to measure distances [1-absolute 281 (correlation coefficients)], and hierarchical clustering was conducted using Morpheus.<sup>36</sup>. 282 Participants were classified into outcome groups based on self-reported general health status 283 before and after vaccination. The tests were all two-sided and Bonferroni-corrected P-values less 284 than 0.05 were considered statistically significant.

285 Differences in SARS-CoV-2 T-cell responses, antibody levels, anti-viral antibody levels 286 against common viruses and autoantibody levels among symptom outcome groups were also 287 compared using Kruskal-Wallis tests. Further, to estimate the average differences in expression of 288 each cytokine over the course of vaccination we used linear mixed models via Restricted 289 Maximum Likelihood (REML) regression, estimating the cytokine expression over all three 290 timepoints amongst three symptom outcome groups: those who did not improve or felt worse at 291 weeks 6 and 12 post vaccination (n=3; Same/Worse), those who showed marginal improvement 292 (n=2, Marginal [i.e. Better week 6; then Worse week 12]) and those who reported improvement 293 (n=7, Better). The model incorporated a random effect for each individual as a random intercept, 294 nested within their respective symptom outcome groups. The fixed effects in the model included 295 the symptom outcome and time, along with an interaction term between them to investigate any 296 potential modifying effect of time on the symptom outcome group. The analysis was conducted 297 using the JMP statistical software platform (JMP<sup>®</sup> Pro 17.0.0).

- Statistical tests were performed using R (v 4.2.2)<sup>35</sup>, GraphPad PRISM(v 9.5.1), and JMP
   statistical software platform (JMP<sup>®</sup> Pro 17.0.0).
- 300

#### 301 Machine Learning

302 Unsupervised hierarchical clustering was conducted on 162 plasma-derived analytes 303 obtained from the multiplex proteomic assays to assess patterns of expression across the cohort 304 using the JMP platform (JMP<sup>®</sup> Pro 17.0.0). Data was standardized by factor and clustering was 305 done based on Ward's distance.

306 To further identify predictors of symptom improvement from the 162 plasma-derived 307 analytes, we used Partial Least Squares (PLS) analysis via the Non-linear iterative partial least 308 squares (NIPALS) algorithm with k-fold cross validation (k=5). The analysis was conducted using the JMP statistical software platform (JMP® Pro 17.0.0). All plasma factors and sex were 309 310 incorporated into the model. Final analysis involved reduction to 4 principal components, which simultaneously minimized the Van der Voet's T-squared statistic (0.00, P=1.00) and the Root 311 312 Mean PRESS (0.27) accounting for a sizeable portion of the variance in the data (cumulative 313 pseudo-R-squared= 0.98). Post-analysis, the Variable Importance on Projection (VIP) score was 314 generated for each feature and bootstrapped using Bayesian Bootstrapping. Bias-corrected 95% 315 confidence intervals were calculated. Only features with 95% confidence intervals above the

316 threshold cutoff of 0.8, corresponding to the standard threshold for importance,<sup>37,38</sup> were 317 considered significant.

318

#### 319 **Results**

320 Among 429 individuals screened between May 3, 2021 and February 2, 2022, 22 met 321 inclusion criteria and consented to participate and 16 individuals completed the baseline survey 322 and subsequently received a first dose of a COVID-19 vaccine; 14 completed all four surveys. 323 People not enrolled had already received a vaccine, did not plan to be vaccinated, or were not able 324 to travel to New Haven for biospecimen collection. The median age of the 16 included participants 325 was 54 years (range 21-69), 13 (81%) were female, and 14 (88%) identified as Non-Hispanic 326 White (Table 1). Immunophenotyping assays were completed on a subset of 11 out of 16. All 327 participants reported that they tested positive for COVID-19 at least once with most reporting a 328 PCR-based test (n=10, 62%).

329

#### **330 Pre-vaccination health and symptoms**

331 At baseline, on participants' worst days, 9 (56%) felt they were 50% or less of their health 332 before COVID-19. On participants' best days, 7 (44%) reported feeling 51-75% of their health 333 before COVID-19. The median number of symptoms per participant before vaccination was 23 334 (Q1-Q3, 13.8-27). The most frequently reported symptoms, in order, were brain fog (81%), fatigue (75%), difficulty concentrating (69%), difficulty sleeping (62%), heart palpitations (56%), 335 336 shortness of breath or difficulty breathing (56%), anxiety (50%), memory problems (50%), 337 dizziness (44%), feeling irritable (44%) (Figure 1). Three (19%) participants were previously 338 hospitalized due to COVID-19 and 4 (25%) visited the hospital or were hospitalized for COVID-339 19 more than 2 weeks after onset of acute disease.

340

#### 341 **Post-vaccination changes in overall health**

Eleven of 16 participants (69%) received the Pfizer-BioNTech vaccine (Comirnaty<sup>®</sup>), 3 (19%) received the Janssen vaccine as their first dose, and 2 (13%) received the Moderna vaccine (SpikeVax<sup>®</sup>). Nine of 13 participants (69%) recommended to receive a second dose in the primary series reported doing so (i.e., Janssen's vaccine in the primary series was single dose). One

346 participant was hospitalized for chest pain three days after receiving their first vaccine dose and 347 again after their second dose.

348 Two weeks after vaccination, 6 out of 14 participants with completed surveys reported their 349 health was better (43%), 3 (21%) said their health was the same, 1(7%) reported worse health, and 350 4 (29%) were not sure of a change (Figure 2). At 6 weeks after vaccination, 11 out of 14 (79%) 351 said their health was better than before vaccination, 2 (14%) reported the same health, and 1 (7%) 352 reported worse health. The participant with worse health 2 weeks after vaccination reported better 353 health at 6 weeks. At 12 weeks, 10 out of 16 (62%) reported better health, while 3 (19%) reported 354 the same health and 3 (19%) reported worse health. Two participants who reported better health at 355 6 weeks reported worse health at 12 weeks, which we classified as marginal improvement in 356 subsequent analyses).

The median number of symptoms per participant initially decreased from 23 (Q1-Q3 13.8-27, n=16) before vaccination to 19.5 (Q1-Q3 12-30.3, n=14) 2 weeks after vaccination, further declining to 17.5 (Q1-Q3 12.3-25.5, n=14) and 15.5 (Q1-Q3 12.5-24.5, n=16) at 6 and 12 weeks after vaccination, respectively.

361 Among the ten most common symptoms experienced at baseline, fatigue and brain fog 362 remained common with 12 (75%) and 11 (69%) participants still reporting these symptoms 12 363 weeks after vaccination (Figure 1). Fewer participants reported difficulty concentrating or 364 focusing at 12 weeks compared with before vaccination (8 [50%] at 12 weeks vs. 11 [69%] before 365 vaccination). Other symptoms decreased modestly over time. The proportion of participants 366 reporting fatigue (12 [75%]), heart palpitations (9 [56%]), and anxiety (8 [50%]) was the same at 367 12 weeks as before vaccination. The proportion of the ten most common symptoms at each survey 368 are presented in Supplementary table 2.

369 Symptom burden appeared to decrease after vaccination on both physical and social effect 370 scales (Figure 3). Before vaccination, the median physical effect score for all symptoms was 68.5 371 (Q1-Q3 37.5-84, range 13-138, n=16) and the median social effect score was 36.5 (Q1-Q3 14-372 51.5, range 1-84, n=16), where higher values represent worse symptom burden. Compared to 373 before vaccination, the median physical effect score decreased to 46.5 (Q1-Q3 21.3-67.3, range 5-374 128, n=14) at 2 weeks after the first COVID-19 vaccine dose, then 36.5 (Q1-Q3 17.8-52.3, range 375 9-104, n=14) 6 weeks after vaccination, and 38.5 (Q1-Q3 15-49.5, range, 0-80, n=16) 12 weeks 376 after vaccination. At 2 weeks after the first COVID-19 vaccine dose, the median social effect score

decreased to 27.5 (Q1-Q3 7.3-34, range 1-80, n=14), then 23 (Q1-Q3 11-36.8, range 2-102, n=14)
6 weeks after vaccination, and 19 (Q1-Q3 3.8-27.5, range 0-61, n=16) 12 weeks after vaccination.

380 SARS-CoV-2-specifc T-cells and antibody responses

381 To characterize the T-cell responses to SARS-CoV-2, sequencing of the CDR3 regions of 382 T-cell receptor- $\beta$  (TCR- $\beta$ ) chains was carried out. There was a significant increase in spike protein 383 (Figure 4a; P<sub>adjusted</sub>=0.012, V1(Figure 4b; P<sub>adjusted</sub>=0.011) and V3 (Figure 4c; P<sub>adjusted</sub>=0.011) classifier scores at 6 weeks post-vaccination, which was indicative of an increase in SARS-CoV-384 385 2 specific T-cell clonal depth and breadth upon vaccination. By contrast and as expected, no 386 significant differences were observed in classifier scores for non-spike protein TCRs with 387 vaccination (Figure 4d; pre-vaccination vs 6 weeks: P<sub>unadjusted</sub>= 0.65; pre-vaccination vs 12 weeks: 388  $P_{unadjusted} = >0.99$ ). There were some individuals who retained high SARS-CoV-2 specific TCR 389 clonality at 12 weeks post-vaccination, however the differences in model scores were not 390 statistically significant in comparison with pre-vaccination. There was a significant decrease in V3 391 classifier score at 12 weeks post-vaccination as compared to 6 weeks (Padjusted=0.011), however 392 this observation was not replicated using the V1 or spike specific classifier scores.

393 Next, SARS-CoV-2 antibody responses were evaluated. A significant increase in anti-S1 394 IgG (Figure 4e; pre vs 6 weeks: P<sub>adjusted</sub>= 0.003, pre vs 12 weeks: P<sub>adjusted</sub>= 0.003) and anti-RBD 395 IgG (Figure 4f; pre vs 6 weeks: P<sub>adjusted</sub>=0.003, pre vs 12 weeks: P<sub>adjusted</sub>=0.003) levels at 6 weeks 396 and 12 weeks post-vaccination was observed without any observed significant rise in anti-N IgG 397 levels (Figure 4g; pre vs 6 weeks: P<sub>unadjusted</sub>= 0.97, pre vs 12 weeks: P<sub>unadjusted</sub>= 0.37). The anti-S1 398 and anti-RBD IgG antibody levels peaked at 6 weeks (median anti-S1 IgG: 8.8×10<sup>4</sup> ng/mL; median 399 anti-RBD IgG: 5.0×10<sup>5</sup> ng/mL) with a marginal decrease at 12 weeks (median anti-S1 IgG: 400  $5.8 \times 10^4$  ng/mL; median anti-RBD IgG:  $2.2 \times 10^5$  ng/mL). To further validate the humoral responses 401 attributed to vaccination, SARS-CoV-2 spike protein reactivities were assessed using REAP. 402 Participant antibody reactivities against Beta, Delta, Epsilon, and Omicron variant RBD epitopes 403 were independently evaluated. A significant increase in reactivity across all non-Omicron RBD 404 epitopes at 6 weeks post-vaccination (Supplementary figures 1a-c) and the Epsilon variant across 405 6- and 12-weeks post-vaccination (Figure 4h; pre vs 6 weeks: P<sub>adjusted</sub>= 0.011, pre vs 12 weeks: 406 Padjusted=0.023) was observed.

407

#### 408 IgG responses to herpesviruses and autoantibodies to the extracellular proteome

409 Given that latent virus reactivation has been a hypothesis behind Long COVID 410 pathobiology and evidence of recent Epstein-Barr Virus (EBV) reactivation has been 411 reported,<sup>30,39,40</sup> anti-viral REAP reactivities against two families of common viral pathogens 412 namely, Coronaviridae (human SARS-CoV-1 viruses) and Herpesviridae, were assessed. Rubella 413 vaccine spike antigen served as internal control as no changes were expected in reactivities with 414 COVID-19 vaccination. As expected, there was a significant increase in REAP scores against 415 SARS-COV-1 RBD upon vaccination at 6 weeks (Figure 4i; P<sub>adjusted</sub>= 0.05). This increase was 416 maintained at 12 weeks, despite not being statistically significant after multiple testing correction 417 (Punadjusted=0.031; Padjusted=0.09). Herpesvirus reactivities varied across participants. However, no 418 significant decrease in reactivities was observed post-vaccination among the herpesvirus antigens 419 tested including EBV (Figure 4i; Supplementary table 3). Additionally, no differences in median 420 reactivities were observed against EBV proteins p23 (Punadjusted=0.65) and gp42 (Punadjusted=0.06) 421 across outcome groups at 6 and 12 weeks post-vaccination (Figures 4j & 4k).

422 Next, given prior reports of elevated autoantibodies targeting the exoproteome in severe acute COVID19,<sup>41</sup> we assessed for changes in extracellularly targeted autoantibodies during 423 424 vaccination (Supplementary figure 2a). No difference in the number of autoantibody reactivities 425 at baseline (Supplementary figure 2b) or in the mean REAP score delta, representing the change 426 in autoantibody magnitude over time (Supplementary figure 2c), between the groups was 427 observed. Overall, autoantibodies were stable over time during vaccination (Supplementary 428 figures 2c-e), with the mean REAP score delta close to 0 for all groups. These results are in 429 concordance to a previous report focusing on autoantibody dynamics during SARS-CoV2 mRNA 430 vaccination in healthy individuals without Long COVID.<sup>42</sup>

431

#### 432 Correlation between SARS-CoV-2 specific TCR and antibody levels

To further evaluate the relation between SARS-CoV-2 specific TCR scores with antibody levels and to assess the concordance among the orthogonal methods of antibody detection, correlation analyses were carried out. Three distinct clusters emerged when distances were calculated based on correlation values among TCR classifier scores and anti-SARS-CoV-2 antibody concentration as well as between ELISA and REAP assays at different timepoints. Each cluster indicated that there was a general concordance in antibody levels using orthogonal methods

439 and TCR scores based on Spearman's r ( $r_s$ ) and unadjusted p-values (Figure 4l, Supplementary 440 tables 4 and 5). It was also observed that higher numbers of pre-vaccination SARS-CoV-2 specific 441 TCR repertoire resulted in higher titers of antibodies both at pre-vaccination, 6- and 12-weeks 442 post-vaccination along with an increase in spike protein specific TCR repertoire. Despite visually 443 strong correlation patterns, due to the small sample size, only anti-SARS-CoV-2 S1 and anti-RBD 444 antibody levels as detected by ELISA at pre-vaccination timepoint and at 12 weeks were 445 statistically significant after multiple testing corrections (pre-vaccination:  $r_s = 0.96$ ,  $P_{adjusted} = 0.021$ ; 12 weeks post-vaccination:  $r_s = 0.98$ ,  $P_{adjusted} = 0.003$ ; Supplementary table 6). 446

447 No significant differences were observed between post-vaccination increase in SARS-448 CoV-2 specific TCR classifier scores and improvement in overall health status [spike protein 449 ( $P_{unadjusted}=0.82$ ), V1( $P_{unadjusted}=0.65$ ), V3 ( $P_{unadjusted}=0.56$ , and non-spike ( $P_{unadjusted}=0.11$ )]. 450 Similarly, no differences were also observed in self-reported health status and increase in anti-451 SARS-CoV-2 antibody levels [anti-S1 ( $P_{unadjusted}=0.73$ ), anti-RBD ( $P_{unadjusted}=0.48$ ) and anti-N 452 ( $P_{unadjusted}=0.94$ )].

453

#### 454 Soluble immune mediators

To understand the impact of vaccination on the cytokine, hormone, and proteomic profiles of individuals with Long COVID, unsupervised hierarchical clustering of 162 analytes measured in their plasma was first conducted (**Figure 5a**). Clustering analysis showed a consistent pattern in their plasma expression profiles at 6- and 12-weeks post-vaccination. Samples clustered by individual and not by timepoint post-vaccination, suggesting an entrenchment in the cytokine profile of each individual that was not significantly affected by vaccination.

461 To understand the relationship of these plasma-derived analytes with post-vaccine 462 symptom outcomes, the average expression levels of each analyte was compared over all three 463 timepoints amongst three symptom outcome groups: those who did not improve or felt worse at 464 weeks 6 and 12 post vaccination (n=3; Same/Worse), those who showed marginal improvement (n=2, Marginal [i.e. Better week 6; then Worse week 12]) and those who reported improvement 465 466 (n=7, Better). To do so we constructed a linear mixed model using restricted maximum likelihood 467 (REML) regression for each cytokine and accounted for both time and the interaction of time with 468 each outcome group. Thirty-five factors were found to be significant amongst these subgroups, 469 with the majority being significantly elevated in the Same/Worse group compared with the

470 improved group. Most interferon factors we measured showed some elevation amongst the 471 Same/Worse group, including IFN- $\beta$  and IFN- $\alpha$  which were found to be significantly elevated in 472 the Same/Worse group compared to the improved group (Figures 5b-d). Ciliary neurotrophic 473 factor (CTNF; a neuropeptide that is released by the hypothalamus), IL-11, and SCF were also 474 significantly elevated in the Same/Worse group compared to the improved group (Figure 5e). 475 Other neuropeptides were noted to be elevated amongst the marginal group including oxytocin, 476 neurotensin, substance P and MSH (Figure 5b). Notably, soluble IL-6 receptor (sIL-6R; an anti-477 inflammatory protein responsible for mitigating IL-6 signaling), was significantly higher amongst 478 those who showed improvement compared to the Same/Worse group (Figure 5h).

479 We further employed Partial Least Squares (PLS) analysis with 5-fold cross validation on 480 all 162 analytes to determine feature importance as predictors of symptom outcome and evaluate 481 concordance with the significant features obtained from our LMM models. Final analysis 482 involved reduction to 8 components, accounting for a sizeable portion of the variance in the data 483 (cumulative pseudo-R-squared=0.99). The top two significant predictors of the PLS analysis for 484 non-improvement were IFN- $\beta$  and CNTF respectively (Figure 5i). The top significant predictor 485 of improvement was sIL-6R (Figure 5i), while sgp130, an important immunological partner to 486 sIL-6R, was also associated with improvement, passing the initial VIP threshold criteria, though 487 not the additional bootstrapping threshold criteria. Taken together these results suggested that 488 high IFN and neuropeptide signaling were predictors of non-improvement while those involved 489 in mitigating cytokine signaling, namely sIL-6R, was a predictor of improvement.

490

#### 491 **Discussion**

492 In this prospective cohort study of 16 vaccination-naïve individuals with Long COVID and 493 significant symptoms at baseline, it was observed that most people improved or stayed the same 494 during follow-up, but some experienced worsening. This study lacked concurrent controls and was 495 small, so it is challenging to make definitive statements about the effect of vaccination, particularly 496 since many people with Long COVID have fluctuations in their symptoms. However, the fact that 497 symptom burden decreased on average and more people improved than worsened suggests that the 498 vaccination was not overtly harmful. Future studies with controls are needed to understand the 499 effect of vaccination on Long COVID symptoms.

500 Our findings are consistent with other studies and systematic reviews reporting 501 improvement or non-significant change in self-reported health among people with Long COVID 502 who were vaccinated for the first time.<sup>18,43–45</sup> A single-center observational study in the United 503 Kingdom identified 44 Long COVID patients (reporting a median of 4.1 and 3.6 symptoms per 504 patient) who had received at least one dose of a COVID-19 vaccine and interviewed at 1 month 505 and 8 months post-vaccination with the SF-36 and Warwick and Edinburgh Mental Wellbeing 506 scores.<sup>46</sup> After adjustment, health status measured with these instruments at 8 months did not differ 507 compared to Long COVID patients who were not vaccinated. In an online cross-sectional survey 508 study of 2,094 people in Switzerland, 35.5% of participants reported that their Long COVID 509 symptoms improved, 28.7% reported their symptoms were stable, and 3.3% reported their symptoms worsened after vaccination.<sup>47</sup> In a French target trial emulation study from the 510 511 ComPaRe Long COVID cohort, COVID-19 vaccination was associated with a reduction in Long 512 COVID severity and symptom burden at 120 days compared with those unvaccinated.<sup>48</sup>

513 Possible mechanisms of Long COVID have been proposed as: 1) a persistent viral reservoir 514 or "viral ghost," which are fragments of the virus (RNA, proteins) that linger after the infection 515 has been cleared but are still capable of stimulating the immune system; 2) an autoimmune 516 response induced by the infection; 3) reactivation of latent viruses; and 4) tissue dysfunction that results from inflammation triggered by the infection.<sup>14,20</sup> Under these hypotheses, COVID 517 518 vaccination may alleviate Long COVID symptoms through vaccine-induced T cells and antibody 519 responses that may be able to eliminate the viral reservoir, and the "viral ghost," diversion of 520 autoreactive leukocytes, or removal of inflammatory sources leading to tissue dysfunction. 521 Vaccination could also indirectly contribute to the control of latent virus reactivation by restoring 522 proper T and B cell immunity against these herpesviruses.

523 Albeit with low sample sizes, this study provides evidence for alleviation of symptoms 524 among Long COVID participants upon vaccination, along with an expected increase in SARS-525 CoV-2 specific T-cell repertoire and anti-SARS-CoV-2 spike protein specific IgG levels. 526 However, clear results of hypothesis 1 (persistent viral reservoir) testing will be available once the 527 results of the Paxlovid trials (NCT0559536949, NCT0566809110, NCT0582389650, NCT05576662<sup>11</sup>) and monoclonal anti-spike antibody (NCT05877508) are shared with the 528 529 scientific community. In addition, a recent study did not find evidence of changes in circulating viral proteins in response to vaccination in those with Long COVID.<sup>19</sup> 530

531 Our study found that the plasma-derived soluble analyte profile showed a very stable 532 pattern before and after vaccination, suggesting that vaccines had a minimal effect on the cytokine 533 dynamics of individuals at least at the time points measured. Without concurrent controls, it is 534 difficult to assess if this phenomenon is unique to individuals with Long COVID or is similar in 535 controls. Nevertheless, an overall elevated cytokine pattern-namely in interferon and 536 neuropeptide signaling-was detected among those who did not improve or showed only marginal 537 symptomatic improvement post-vaccination. These findings pose an interesting observation that 538 may help identify predictors of improvement versus non-improvement in larger studies. Elevated 539 interferon signaling suggests the possibility of an ongoing infectious viral process in these 540 individuals. The lack of improvement post-vaccination and the persistence of this signaling suggest 541 that either the vaccine was incapable of producing the necessary antibodies and T cells that clear 542 persistent infection when a viral reservoir exists, or that the main driver of disease in such 543 individuals is not SARS-CoV-2, but re-emergence of a latent infection such as EBV or 544 autoimmunity. More work will be needed to both confirm the findings of this small study and in 545 turn to decipher a possible mechanism for elevation of interferon in these individuals, including 546 the exploration of CNS involvement due to the elevation of neuropeptides which were also 547 associated with poor improvement. A recent study has shown that the persistence of IFN signaling can lead to lower serotonin levels, a critical neurotransmitter<sup>51</sup> which may also be involved in the 548 549 symptom profile of individuals and or these outcomes. However, given the small sample size of 550 our study, these possibilities can only be interpreted as speculative.

551 The limitations of this study include the lack of concurrent controls (i.e., individuals with 552 Long COVID who remained unvaccinated or had a sham vaccination and completed the same 553 surveys and provided biospecimens) to compare to our participants against and that most 554 participants were recruited from an online Long COVID community and had to travel to New 555 Haven, Connecticut for biospecimen collection and thus may not be representative of those with 556 Long COVID. Participants had to be physically able to travel, so they may have been less likely 557 to have severe Long COVID; at the same time, individuals more severely affected by Long COVID 558 may have been more motivated to meet the travel requirements to participate in the study, as well 559 as to be vaccinated. Participants also had to have the financial means and occupational flexibility 560 to travel. Moreover, generalizability to all individuals with Long COVID cannot be determined 561 especially for those who have developed Long COVID symptoms later in the pandemic (e.g., post-

562 Omicron era). However, this study's strengths are the prospective study design of vaccine naïve 563 individuals with Long COVID, an increasingly rare population, with assessment of symptom 564 burden, degree of physical and social disability, and immunophenotyping at multiple timepoints 565 after vaccination.

In conclusion, in this study of 16 individuals living with Long COVID, most people improved or stayed the same, though some had worsening symptoms. Vaccination resulted in increase in SARS-CoV-2 specific T-cell populations and anti-spike protein IgG levels. The top predictor of participant non-improvement upon vaccination were IFN- $\beta$  and CNTF, and sIL-6R was found to be a predictor of improvement. Future studies are needed to better understand the impact of vaccination in the health of people living with Long COVID.

572

#### 573 Acknowledgements

We want to thank the participants who contributed to the study and patient groups for their recruitment efforts and study design contributions. This work was supported in part by funds from Fred Cohen and Carolyn Klebanoff and by grants from National Institute of Allergy and Infectious Diseases (R01AI157488 to A.I.), the Howard Hughes Medical Institute Collaborative COVID-19 Initiative (to A.I.), and the Howard Hughes Medical Institute (to A.I.). J. J., T.T., and B. B. received research support from Yale University from the Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938).

581

#### 582 References

I. Iacobucci, G. Long covid: Damage to multiple organs presents in young, low risk patients.
 *BMJ* m4470 (2020) doi:10.1136/bmj.m4470.

Huang, Y. *et al.* COVID Symptoms, Symptom Clusters, and Predictors for Becoming a
 Long-Hauler Looking for Clarity in the Haze of the Pandemic. *Clin. Nurs. Res.* 31, 1390–
 1398 (2022).

588 3. Nehme, M. *et al.* COVID-19 Symptoms: Longitudinal Evolution and Persistence in
589 Outpatient Settings. *Ann. Intern. Med.* 174, 723–725 (2021).

590 4. O'Mahoney, L. L. *et al.* The prevalence and long-term health effects of Long Covid among

- 591 hospitalised and non-hospitalised populations: a systematic review and meta-analysis.
- *eClinicalMedicine* **55**, (2023).

- 593 5. Greenhalgh, T., Knight, M., A'Court, C., Buxton, M. & Husain, L. Management of postacute covid-19 in primary care. *BMJ* 370, m3026 (2020).
- 595 6. Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626–631 (2021).
- 596 7. Davis, H. E. *et al.* Characterizing long COVID in an international cohort: 7 months of
- 597 symptoms and their impact. *EClinicalMedicine* **38**, 101019 (2021).
- 598 8. Lambert, N. *et al.* The other COVID-19 survivors: Timing, duration, and health impact of
  599 post-acute sequelae of SARS-CoV-2 infection. *J. Clin. Nurs.* n/a,.
- 600 9. Peluso, M. An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess
- 601 the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in
- 602 Individuals With Long COVID (outSMART-LC).
- 603 https://clinicaltrials.gov/study/NCT05877508 (2023).
- 604 10. Krumholz, H. M. An Interventional Decentralized Phase 2, Randomized, Double-Blind, 2-
- 605 Arm Study to Investigate the Efficacy and Safety of Orally Administered
- 606 Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Participants With Long
- 607 *COVID*. https://clinicaltrials.gov/study/NCT05668091 (2023).
- 608 11. Stanford University. Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized
- 609 Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC.
- 610 https://clinicaltrials.gov/study/NCT05576662 (2023).
- 611 12. Yonker, L. Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to
- 612 Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID
- 613 *in Children and Young Adults*. https://clinicaltrials.gov/study/NCT05747534 (2023).
- 614 13. Proal, A. D. *et al.* SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). *Nat.*615 *Immunol.* 24, 1616–1627 (2023).
- 616 14. Choutka, J., Jansari, V., Hornig, M. & Iwasaki, A. Unexplained post-acute infection
- 617 syndromes. *Nat. Med.* **28**, 911–923 (2022).
- 618 15. Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,
  619 mechanisms and recommendations. *Nat. Rev. Microbiol.* 21, 133–146 (2023).
- 620 16. Natarajan, A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA
- 621 suggest prolonged gastrointestinal infection. *Med N. Y. N* **3**, 371-387.e9 (2022).

- 622 17. Swank, Z. et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2
- Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 76, e487–e490 (2023).
- 18. Notarte, K. I. *et al.* Impact of COVID-19 vaccination on the risk of developing long-COVID
  and on existing long-COVID symptoms: A systematic review. *EClinicalMedicine* 53,
- 627 101624 (2022).
- 19. Nayyerabadi, M. *et al.* Vaccination after developing long COVID: impact on clinical
  presentation, viral persistence and immune responses. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.* S1201-9712(23)00720–8 (2023) doi:10.1016/j.ijid.2023.09.006.
- 631 20. Iwasaki, A. & Putrino, D. Why we need a deeper understanding of the pathophysiology of
  632 long COVID. *Lancet Infect. Dis.* 23, 393–395 (2023).
- 21. Duradoni, M., Gursesli, M. C., Materassi, L., Serritella, E. & Guazzini, A. The Long-COVID
  Experience Changed People's Vaccine Hesitancy but Not Their Vaccination Fear. *Int. J.*
- 635 *Environ. Res. Public. Health* **19**, 14550 (2022).
- 636 22. Massey, D. *et al.* Change in Symptoms and Immune Response in People with Post-Acute
  637 Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination.
- 638 2021.07.21.21260391 Preprint at https://doi.org/10.1101/2021.07.21.21260391 (2021).
- 639 23. Iwasaki, A. How Vaccines Might Improve Long Covid. *Elemental*
- 640 https://elemental.medium.com/how-vaccines-might-improve-long-covid-c1f41c4d7378641 (2021).
- 642 24. Prof. Akiko Iwasaki [@VirusesImmunity]. This video shows that vaccines have helped some
  643 people with #longCOVID with their symptoms. While the numbers are still small in some
- people with monge e vib with their symptoms. While the numbers are sufficient in some
- 644 groups, there are encouraging signs (also via @DanielGriffinMD). I present my hypothesis
- on how vaccines might improve #LongCovid 👅 (1/). *Twitter*
- 646 https://twitter.com/VirusesImmunity/status/1366067849480048643 (2021).
- 647 25. Vaccine Survey Patient Led Research Collaborative.
- 648 https://patientresearchcovid19.com/vaccine-survey/.
- 649 26. Johns Hopkins COVID Long Study. *Johns Hopkins COVID Long Study* https://covid650 long.com/.
- 651 27. Lambert, N. J., Corps, S., El-Azab, S., Yu, L. & Esperanca, A. Fever Scans Offer False
- 652 Sense of Security for Stopping the Spread of COVID-19. (2020).

- 653 28. Lambert, N. J. & Corps, S. COVID-19 "Long Hauler" Symptoms Survey Report. (2020).
- 654 29. Assaf, G. *et al.* Report: What Does COVID-19 Recovery Actually Look Like? Patient Led
   655 Research Collaborative. https://patientresearchcovid19.com/research/report-1/.
- 656 30. Klein, J. *et al.* Distinguishing features of Long COVID identified through immune profiling.
- 657 *MedRxiv Prepr. Serv. Health Sci.* 2022.08.09.22278592 (2022)
- 658 doi:10.1101/2022.08.09.22278592.
- 659 31. Snyder, T. M. et al. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2
- 660 Infection at Both Individual and Population Levels. *MedRxiv Prepr. Serv. Health Sci.*661 2020.07.31.20165647 (2020) doi:10.1101/2020.07.31.20165647.
- 662 32. Adaptive Biotechnologies Corporation. Emergency Use Authorization (EUA) Summary T-

663 Detect COVID Test. (2021).

33. Klinger, M. et al. Multiplex Identification of Antigen-Specific T Cell Receptors Using a

- 665 Combination of Immune Assays and Immune Receptor Sequencing. *PloS One* 10, e0141561666 (2015).
- 34. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for
   removing batch effects and other unwanted variation in high-throughput experiments.

669 *Bioinformatics* **28**, 882–883 (2012).

- 670 35. R Core Team. R: A language and environment for statistical computing.
- 671 36. Morpheus. https://software.broadinstitute.org/morpheus/.
- 37. Wold, S., Johansson, E. & Cocchi, M. PLS: Partial Least Squares Projections to Latent
  Structures. in (1993).
- 674 38. Kubinyi, H. 3D QSAR in drug design : theory, methods and applications. in (2000).
- 39. Su, Y. *et al.* Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell* 185, 881895.e20 (2022).
- 40. Gold, J. E., Okyay, R. A., Licht, W. E. & Hurley, D. J. Investigation of Long COVID
- 678 Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. *Pathog. Basel Switz.* 10,
  679 763 (2021).
- 41. Wang, E. Y. *et al.* Diverse functional autoantibodies in patients with COVID-19. *Nature* 595,
  283–288 (2021).
- 42. Jaycox, J. R. *et al.* SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from
  humoral autoimmunity. *Nat. Commun.* 14, 1299 (2023).

- 43. Tsuchida, T. *et al.* Relationship between changes in symptoms and antibody titers after a
  single vaccination in patients with Long COVID. *J. Med. Virol.* 94, 3416–3420 (2022).
- 686 44. Watanabe, A., Iwagami, M., Yasuhara, J., Takagi, H. & Kuno, T. Protective effect of
- 687 COVID-19 vaccination against long COVID syndrome: A systematic review and meta688 analysis. *Vaccine* 41, 1783–1790 (2023).
- 45. Byambasuren, O., Stehlik, P., Clark, J., Alcorn, K. & Glasziou, P. Effect of covid-19
  vaccination on long covid: systematic review. *BMJ Med.* 2, e000385 (2023).
- 46. Arnold, D. T. *et al.* Are vaccines safe in patients with Long COVID? A prospective
  observational study. 2021.03.11.21253225 Preprint at
- 693 https://doi.org/10.1101/2021.03.11.21253225 (2021).
- 47. Nehme, M. *et al.* Symptoms After COVID-19 Vaccination in Patients with Post-Acute
  Sequelae of SARS-CoV-2. *J. Gen. Intern. Med.* 37, 1585–1588 (2022).
- 48. Tran, V.-T., Perrodeau, E., Saldanha, J., Pane, I. & Ravaud, P. Efficacy of first dose of
- 697 covid-19 vaccine versus no vaccination on symptoms of **patients** with long covid: target trial
  698 emulation based on ComPaRe e-cohort. *BMJ Med.* 2, e000229 (2023).
- 699 49. Zimmerman, K. O. *RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions*
- for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae
   of SARS-CoV-2 Infection (PASC). https://clinicaltrials.gov/study/NCT05595369 (2023).
- 50. Brodin, P. An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of
- 703 Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritonavir in Non-
- 704 *hospitalized Adult Participants Suffering From Post-COVID.*
- 705 https://clinicaltrials.gov/study/NCT05823896 (2023).
- 51. Wong, A. C. *et al.* Serotonin reduction in post-acute sequelae of viral infection. *Cell* 186,
  4851-4867.e20 (2023).
- 708

## **Table and Figures**

Characteristic	n=16 (%)
Age, Median (Min-Max)	54 (21-69)
Missing	1
Gender	
Female	13 (81%)
Male	3 (19%)
Race/ethnicity	
American Indian/Alaska Native	1 (6%)
Hispanic	1 (6%)
Non-Hispanic White	14 (88%)
Tested for COVID-19	16 (100%)
Hospitalized due to COVID-19	3 (19%)
Hospitalized for COVID-19 or visited a hospital more than 2	4 (25%)
weeks after infection	
Test type	
Antigen test	2 (12%)
Not sure	4 (25%)
PCR test	10 (62%)
On your best days would you say you are of health before	
COVID-19	
0-25% of health before COVID-19	0
26-50% of health before COVID-19	1 (6%)
51-75% of health before COVID-19	7 (44%)
76-100% of health before COVID-19	8 (50%)
On your worst days would you say you are of health before	
COVID-19	
0-25% of health before COVID-19	5 (31%)
26-50% of health before COVID-19	4 (25%)
51-75% of health before COVID-19	6 (38%)
76-100% of health before COVID-19	1 (6%)

## 

712 Table 1: Baseline characteristics



#### 718 719

#### 720 Figure 1: Trends of the ten most common symptoms before vaccination.

The proportion of symptoms experienced was calculated at each survey as the number of participants experiencing each symptom (i.e., symptom reported and non-zero response to the physical or social effect scales) out of the participants who completed the given survey. Data missing for n=2 at 2 weeks and n=2 at 6 weeks.





- 726 727
- 728



- 731 Participants were asked "Would you say that your overall health, as compared to your health before
- the vaccine, is worse, better, or the same?" at each post-vaccination survey. Data missing for n=2
- 733 at 2 weeks and n=2 at 6 weeks.



# 734 735

Weeks since first COVID-19 vaccine

736 Figure 3: Distribution of the sum of participants' responses to two measures of symptom 737 severity—physical and social effects—measured before vaccination and surveys sent 2, 6, 738 and 12 weeks after vaccination.

739 To measure physical effect of each symptom from a list of 125 symptoms, participants were asked, 740 "While experiencing these symptoms, how much do/did they bother you in terms of discomfort or 741 pain?" Similarly, to measure social effects, participants were asked, "After quarantine, how much 742 does/did the symptom impair your social or family functioning compared to pre-COVID? 743 Responses for each symptom were scored 0 to 4 (Supplementary table 1) and summed for each 744 participant. Boxplots show the distribution of responses, with points representing the score for 745 each participant and lines showing participants' trajectory across surveys. Data missing for n=2 at 746 2 weeks and n=2 at 6 weeks.



747

748 Figure 4: Vaccination resulted in increase in SARS-CoV-2 T-cell repertoires and specific

749 humoral responses among Long COVID participants.

750 (a) Model scores and binary classifications are plotted against days post-vaccination using spike 751 viral protein specific classifier (b) COVID classifier version 1 (v1) (c) COVID classifier version 752 3 (v3) (d) Non-spike-specific protein classifier (e) Line plots of matched anti-SARS-CoV-2 S1 753 IgG concentrations before, 6 and 12 weeks post-vaccination in Long COVID participants. (f) Line 754 plots of matched anti-SARS-CoV-2 RBD IgG concentrations before, 6 and 12 weeks post-755 vaccination in Long COVID participants. (g) Line plots of matched anti-SARS-CoV-2 N IgG 756 concentrations before, 6 and 12 weeks post-vaccination in Long COVID participants. The color 757 codes denote the reported health status at 6 and 12 weeks post-vaccination, better at both 758 timepoints [teal], no change at both timepoints [blue], better at 6 weeks and worse at 12 weeks 759 [purple] & worse at both timepoints [orange]. (h) Line plots of matched anti-SARS-CoV-2 Epsilon 760 variant reactivity scores against the Spike protein assessed by Rapid Extracellular Antigen 761 Profiling (REAP) (i) Heatmap of REAP reactivities against 10 viral proteins namely, proteins 762 belonging to common viral pathogens from Coronaviridae (human SARS-CoV-1 viruses), 763 Herpesviridae families, and the Rubella vaccine protein. Each protein and each participant 764 timepoint are represented as a row and a column respectively. The participant IDs are mentioned 765 below each column and the numbers after decimal denote the collection timepoints after 766 vaccination (6 weeks= 2; 12 weeks= 3). Statistical significance determined by Wilcoxon Rank 767 tests and corrected for multiple testing using the Bonferroni method. (j) EBV p23 REAP scores 768 among outcome groups. Significance was assessed using Kruskal-Wallis tests. (k) EBV gp42 769 REAP scores among outcome groups. (1) Hierarchical clustering of Spearman Rank correlation 770 coefficients of TCR model scores, antibody concentrations and REAP scores at all three 771 timepoints. Only adjusted p-values of <0.05 are mentioned in line plots and denoted by asterisks 772 in heatmaps.



# Figure 5: Elevated interferon and neuropeptide signaling is associated with poor recovery post-vaccination.

776 (a) Unsupervised hierarchical clustering of plasma-derived analyte expression within the cohort 777 for all three sample timepoints (pre-vaccination, 6 weeks post series completion, and 12 weeks 778 post series completion). Color panel above heatmap shows the symptom outcome subgroup of 779 each individual as indicated by the key. Samples for each individual are labeled by their sample 780 code LC.R.HK.1.00XX.tX, where XX designates the patient ID and tX designates the timepoint 781 (t1 = pre vaccination, t2 = 6 weeks post series completion, and t3 = 12 weeks post series completion).782 Sample label color indicates further categorization into Same/Worse (orange), marginal 783 improvement (i.e., better then worse; purple), and Improved (teal). Color scale is magma and is 784 normalized for each analyte (data table columns) with darker colors indicating higher relative 785 expression and lighter colors indicating lower expression as shown by the key. (b) Expression 786 Heatmap of significant differentially expressed factors between symptom outcome groups 787 (Same/Worse, Marginal, and Improved), as labeled. Each subgroup is further separated by the 788 vaccine timepoint. Each factor was centered and standardized to generate a z-score and colors are 789 representative of expression as indicated by the legend. To show significance between groups, 790 samples were organized with outer brackets of the heatmap indicating the symptom outcome group 791 demonstrating significantly lower expression and inner brackets indicating the comparator group 792 from which significance is derived. Significance was determined using linear mixed models 793 (LMM) via restricted maximum likelihood (REML) regression for log-transformed values, 794 accounting for repeated measures across individuals over time as described in the methods and 795 adjusted for multiple comparisons within each parameter using the Tukey method. (c-h) Example 796 differentially expressed factors between symptom outcome groups as determined by LMM, 797 previously described. (i) Top 20 bootstrapped predictors of symptom outcome (unimproved vs 798 improved), determined by Partial Least Squares (PLS) optimized at eight components. Predictors 799 are ordered by importance with highest importance on the left. Color and direction of each bar 800 represents the relative regression association to unimproved individuals with positive values 801 showing a positive association and negative values showing a negative association. Color is 802 determined by regression as shown. Details of NIPALS and detailed results can be found in the 803 methods and in extended data, respectively.

804

805

806

807

808

809

810

811



#### Supplementary Figure 1: Increased reactivity in non-Omicron specific RBD epitopes post-

#### vaccination.

(a) Line plots of matched anti-SARS-CoV-2 Beta variant reactivity scores against the Spike protein

assessed by Rapid Extracellular Antigen Profiling (REAP) (b) Anti-SARS-CoV-2 Delta variant

reactivity scores (c) Anti-SARS-CoV-2 Omicron variant reactivity scores. Statistical significance

was determined by Wilcoxon with Bonferroni correction for multiple comparisons. Only

significant values are mentioned in the graphs.

- 819 820 821





845 Supplementary Figure 2: (a) REAP reactivities across the cohort at the first time point. Each 846 column is one participant, grouped by cohort (B/W = marginal). Each row represents one protein. Reactivities shown have at least one participant with a REAP score  $\geq 1$ . (b) The number of 847 848 autoantibody (aAb) reactivities per individual (ID) by group. Significance was assessed using Kruskal-Wallis tests. (c) Average REAP score delta for autoantibody reactivities per individual 849 from the first to the final time point. Significance was assessed using Kruskal-Wallis tests. For 850 851 the box plots, the central lines indicate the group median values, the top and bottom lines indicate the 75th and 25th percentiles, respectively, the whiskers represent  $1.5 \times$  the interguartile range. 852

Each dot represents one individual. (d) Autoantibody trajectory for one individual during
vaccination. Each line represents one reactivity (red = SARS-CoV2, blue = Herpesvirus, black =
autoantibody. (e) overlay plot of all anti-viral and autoantibodies detected normalized to a starting
REAP score of 0. Each line represents one reactivity.

- 857
- 858

Measure of		Likert scale
symptom severity	Survey questions	response
Physical	"While experiencing these symptoms, how much do/did	Not at all $= 0$
	they bother you in terms of discomfort or pain?"	A little bit $= 1$
Social	"After quarantine, how much does/did the symptom	Somewhat $= 2$
	impair your social or family functioning compared to pre-	Quite a bit $= 3$
	COVID?"	Very much $= 4$

859 Supplementary Table 1: Survey questions assessing the physical and social effects for each

symptom prior to vaccination and at surveys sent 2, 6, and 12 weeks after vaccination.

- 861
- 862

Pre-vaccine (n=16)	2 weeks (n=14)	6 weeks (n=14)	12 weeks (n=16)
Brain fog (81%)	Fatigue (86%)	Fatigue (86%)	Fatigue (75%)
Fatigue (75%)	Brain fog (79%)	Brain fog (79%)	Brain fog (69%)
Difficulty	Difficulty	Difficulty	
concentrating or	concentrating or	concentrating or	Heart palpitations
focusing (69%)	focusing (71%)	focusing (71%)	(56%)
Difficulty sleeping			
(62%)	Anxiety (64%)	Anxiety (57%)	Anxiety (50%)
			Difficulty
Heart palpitations	Heart palpitations	Heart palpitations	concentrating or
(56%)	(57%)	(57%)	focusing (50%)
Shortness of breath or	Shortness of breath or		
difficulty breathing	difficulty breathing		Difficulty sleeping
(56%)	(57%)	Headache (50%)	(50%)
		Shortness of breath or	
		difficulty breathing	Post-exertional
Anxiety (50%)	Feeling irritable (50%)	(50%)	malaise (50%)
Memory problems	Memory problems		
(50%)	(50%)	Diarrhea (43%)	Headache (44%)
	Post-exertional	Difficulty sleeping	Inability to exercise or
Dizziness (44%)	malaise (50%)	(43%)	be active (44%)
			Shortness of breath or
	Difficulty sleeping	Inability to exercise or	difficulty breathing
Feeling irritable (44%)	(43%)	be active (43%)	(44%)

863 **Supplementary Table 2**: Ten most common symptoms prior to vaccination and at surveys sent 2,

- 864 6, and 12 weeks after vaccination. Data missing for n=2 at 2 weeks and n=2 at 6 weeks.
- 865

866 **Supplementary File:** Blank study surveys sent to participants prior to vaccination and 2, 6, and 867 12 weeks after vaccination (PDF) and Supplementary tables 3-6 (Excel file).